BioSpace News Archive

BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the initiation of the Phase 2 PLACIDITY trial of BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine (“Dex”)

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau as well as Dr. David Nutt, one of the Company’s lead DMT consultants, will be discussing the Company’s New DMT Stroke Clinical Research Program at the upcoming Psychedelic Capital Virtual Investment Conference,

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has launched a strategic development collaboration and exclusive supply agreement with PureForm Global, Inc.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced changes to the Phase 3 trial assessing investigational REGEN-COV™ (casirivimab with imdevimab) in non-hospitalized patients (“outpatients”) with COVID-19, following recommendations from the Independent Data Monitoring Committee (IDMC).

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at 12:10 p.m. EST .

Miroculus, Inc., a developer of revolutionary tools for personal lab automation, today announced the completion of a Series B extension, bringing the total capital raised in the series to $45M.

Encouraging signals of anti-tumor activity demonstrated across COM701 Phase 1 combination and monotherapy studies with durable responses, including a complete response, in tumor types typically unresponsive to checkpoint inhibitors

-- Launched EYSUVIS™, First and Only Prescription Therapy Approved Specifically for Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease -- -- Progressing Pipeline Programs to Address Front and Back of Eye Diseases -- -- Cash Position and INVELTYS Revenue Expected to Provide Runway Into at Least 4Q 2022; EYSUVIS Revenue Expected to Provide Additional Runway --

Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) , a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo Adversa and QIXLEEF in Denmark, Norway, Sweden, Finland, and Germany.